Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy

Signal Transduct Target Ther. 2021 Mar 6;6(1):111. doi: 10.1038/s41392-021-00530-6.

Authors

Catarina R Almeida¹, Beatriz H Ferreira^{1

2}, Iola F Duarte³

Affiliations

¹ iBiMED - Institute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.
² CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Aveiro, Portugal.
³ CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Aveiro, Portugal. ioladuarte@ua.pt.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Immunotherapy
Neoplasms* / drug therapy
Proprotein Convertase 9*
Receptors, LDL

Substances

Receptors, LDL
PCSK9 protein, human
Proprotein Convertase 9